Tower Research Capital (TRC)’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-817
| Closed | -$5K | – | 4446 |
|
|
2019
Q4 | $5K | Sell |
817
-3,372
| -80% | -$19.5K | ﹤0.01% | 2737 |
|
|
2019
Q3 | $15K | Sell |
4,189
-4,648
| -53% | -$17.9K | ﹤0.01% | 2705 |
|
|
2019
Q2 | $24K | Buy |
+8,837
| New | +$26.1K | ﹤0.01% | 2070 |
|
|
2018
Q4 | – | Sell |
-4,437
| Closed | -$16K | – | 4659 |
|
|
2018
Q3 | $16K | Buy |
+4,437
| New | +$13.2K | ﹤0.01% | 2504 |
|
|
2017
Q4 | – | Sell |
-10,659
| Closed | -$38.7K | – | 4306 |
|
|
2017
Q3 | $48K | Buy |
+10,659
| New | +$47.3K | ﹤0.01% | 2028 |
|
|
2017
Q1 | – | Sell |
-2,291
| Closed | -$9K | – | 4315 |
|
|
2016
Q4 | $9K | Buy |
2,291
+2,191
| +2,191% | +$11.6K | ﹤0.01% | 2740 |
|
|
2016
Q3 | $1K | Buy |
+100
| New | +$850 | ﹤0.01% | 3445 |
|
|
2016
Q2 | – | Sell |
-1,107
| Closed | -$9K | – | 5281 |
|
|
2016
Q1 | $9K | Buy |
+1,107
| New | +$8.11K | ﹤0.01% | 2118 |
|
|
2015
Q3 | – | Sell |
-9,610
| Closed | -$85K | – | 5128 |
|
|
2015
Q2 | $85K | Sell |
9,610
-7,086
| -42% | -$67K | 0.01% | 980 |
|
|
2015
Q1 | $165K | Buy |
16,696
+15,742
| +1,650% | +$197K | 0.02% | 529 |
|
|
2014
Q4 | $12K | Sell |
954
-4,368
| -82% | -$53.3K | ﹤0.01% | 2021 |
|
|
2014
Q3 | $53K | Buy |
+5,322
| New | +$49.4K | 0.01% | 1484 |
|
|
2014
Q1 | – | Sell |
-17,839
| Closed | -$59K | – | 5171 |
|
|
2013
Q4 | $59K | Buy |
+17,839
| New | +$51.8K | 0.01% | 1258 |
|
|
2013
Q3 | – | Sell |
-4,361
| Closed | -$36K | – | 4987 |
|
|
2013
Q2 | $36K | Buy |
+4,361
| New | +$33.3K | ﹤0.01% | 1200 |
|
Tower Research Capital (TRC)'s ACHN Position: Q1 2020 in Review
Tower Research Capital (TRC) sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 817 shares — an estimated $5K sold.
Tower Research Capital (TRC) first reported a position in ACHN in Q2 2013 and held it in 14 quarters. The position peaked at $165K in Q1 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Tower Research Capital (TRC) reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 817 Achillion Pharmaceuticals shares in Q1 2020, an estimated $5K.
- Tower Research Capital (TRC) first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Tower Research Capital (TRC)'s Achillion Pharmaceuticals position peaked at $165K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.